Search
Satralizumab
go.drugbank.com/drugs/DB15762ApprovedInvestigationalThis novel mechanism effectively increases the duration of action of satralizumab, as it allows for single drug molecules to interact with multiple endogenous IL-6 receptors prior to elimination. … [A218551] It received subsequent approvals in Switzerland and Japan,[A218551] and was approved for use by the FDA in August 2020,[L15566] becoming the 3rd treatment to receive FDA approval for NMOSD (after
Products: ENSPRYNG® SATRALIZUMAB 120MG/ML, ENSPRYNG SOLUTION FOR INJECTION IN PREFILLED SYRINGE 120MG/1MLSalicylic acid
go.drugbank.com/drugs/DB00936ApprovedInvestigationalVet approvedIt has bacteriostatic, fungicidal, and keratolytic actions. Its salts, the salicylates, are used as analgesics.
Mixtures: LOCASALENE 0,2MG/G+30MG/G MERHEM, 30 G, PREPARED COAL TAR 5% ET SALICYLIC ACID 2% OINTMENTProducts: ORIPAN GOLD 100g, Physiogesic Cream 100mg/gmAsunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawn[A32528] It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on April 22, 2016. The commercialization of asunaprevir was cancelled one year later on October 16, 2017.[L1113] … It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b.
Products: SUNVEPRA CAPSULE 100MG, SUNVEPRA® 100MG CÁPSULAS BLANDASOxyphenbutazone
go.drugbank.com/drugs/DB03585ApprovedWithdrawnOxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.
Products: Oxybutazone Tab 100mg, Oxyphenbutazone 100mg TabletsHyoscyamine
go.drugbank.com/drugs/DB00424ApprovedInvestigational[L31548,L31553] Although hyoscyamine is marketed in the United States, it is not FDA approved.[L31548,L31553] … [A228423] It is commonly extracted from plants in the _Solanaceae_ or nightshade family.[A228423] Research into the action of hyoscyamine in published literature dates back to 1826.
Mixtures: Urimar-T, Urimar-TProducts: Ed-spaz, Hyoscyamine ERSotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigational[A187550] Mutant KRAS discovered in 1982 but was not considered a druggable target until the mid-2010s.[A235168] It is the first experimental KRAS inhibitor. … Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen.
Categories: RAS GTPase InhibitorsProducts: LUMAKRAS FILM-COATED TABLET 120MGEvolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalIt is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line therapies. … It is a subcutaneous injection approved by the FDA for individuals on maximum statin therapy who still require additional LDL-cholesterol lowering.
Products: REPATHA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 140MG/ML, Repatha Solution for Injection in Pre-filled Syringe 140mg/mL (evolocumab)Rolitetracycline
go.drugbank.com/drugs/DB01301ApprovedWithdrawnA pyrrolidinylmethyl tetracycline.
Products: Reverin 275mgExenatide
go.drugbank.com/drugs/DB01276ApprovedInvestigationalExenatide was given FDA approval on April 28, 2005[L6106]. It is available as immediate- and extended-release formulations. … It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control[L42690].
Products: BYDUREON® BCISE® 2MG SUSPENSIÓN DE LIBERACIÓN PROLONGADA, BYDUREON POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION IN PRE-FILLED PEN 2MGDesoximetasone
go.drugbank.com/drugs/DB00547ApprovedA topical anti-inflammatory glucocorticoid used in dermatoses, skin allergies, psoriasis, etc.
Products: Topicort Crm 2.5mg/gm, Topicort Ointment 2.5mg/gm